Long-term Gene Therapy in the Eye Using Adenovector
Author Information
Author(s): Hamilton Melissa M., Byrnes Gordon A., Gall Jason G., Brough Douglas E., King C. Richter, Wei Lisa L.
Primary Institution: GenVec, Inc.
Hypothesis
Can the Ad35 adenovector provide prolonged transgene expression compared to the Ad5 serotype following a single injection?
Conclusion
The Ad35 adenovector results in prolonged gene expression and inhibits abnormal blood vessel growth in the eye.
Supporting Evidence
- Ad35-based vectors showed prolonged gene expression compared to Ad5 vectors.
- Therapeutic gene levels from Ad35.PEDF vector inhibited abnormal blood vessel growth.
- Gene expression was monitored for up to 120 days post-injection.
Takeaway
This study shows that a special type of virus can help deliver medicine to the eye for a long time with just one shot, which is better than needing many shots.
Methodology
Mice received one intravitreal injection of either Ad5 or Ad35 vectors, and gene expression was monitored over time.
Limitations
The study was conducted in mice, which may not fully represent human responses.
Participant Demographics
Female C57BL/6 mice, 6-8 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website